Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI110 +/- Sintilimab in r/r DLBCL
NCT05039658Phase 1Unknown
- Sponsor
- Innovent Biologics
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibi110 in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Objective Response Rate up to 24 months and Frequency of adverse events and serious adverse events up to 24 months. Status: unknown.
02
Drugs
ibi110
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05039658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039658.